Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E15.73 EPS (ttm)15.95 Insider Own0.10% Shs Outstand214.42M Perf Week0.28%
Market Cap53.78B Forward P/E11.11 EPS next Y22.57 Insider Trans29.12% Shs Float211.48M Perf Month-9.32%
Income3.48B PEG2.48 EPS next Q4.54 Inst Own90.50% Short Float1.19% Perf Quarter-13.85%
Sales11.53B P/S4.66 EPS this Y10.30% Inst Trans-0.65% Short Ratio1.60 Perf Half Y-11.00%
Book/sh53.24 P/B4.71 EPS next Y10.23% ROA15.90% Target Price318.53 Perf Year-3.45%
Cash/sh13.43 P/C18.67 EPS next 5Y6.34% ROE29.50% 52W Range205.42 - 307.33 Perf YTD-3.98%
Dividend- P/FCF42.41 EPS past 5Y27.40% ROI21.00% 52W High-18.39% Beta0.86
Dividend %- Quick Ratio2.00 Sales past 5Y17.80% Gross Margin86.60% 52W Low22.09% ATR4.63
Employees7400 Current Ratio2.30 Sales Q/Q3.10% Oper. Margin41.60% RSI (14)36.84 Volatility1.52% 1.69%
OptionableYes Debt/Eq0.57 EPS Q/Q-21.80% Profit Margin30.20% Rel Volume0.53 Prev Close252.97
ShortableYes LT Debt/Eq0.52 EarningsApr 25 BMO Payout0.00% Avg Volume1.56M Price250.80
Recom2.20 SMA20-3.15% SMA50-6.36% SMA200-8.63% Volume826,054 Change-0.86%
Mar-16-17Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-16-17Downgrade Leerink Partners Outperform → Mkt Perform
Mar-02-17Initiated Instinet Buy $345
Feb-07-17Upgrade Citigroup Neutral → Buy
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
May-26-17 09:42AM  Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer Zacks
03:53AM  Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound? Zacks
May-25-17 12:35PM  Another top Biogen executive stepping down American City Business Journals
09:50AM  Short Sellers Raise the Stakes in Major Biotechs 24/7 Wall St.
09:16AM  Biogen's Fampyra Conditional Approval Converted to Standard Zacks
08:43AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
May-24-17 05:44PM  Deadly brain infection in German MS patient prompts Roche investigation Reuters
04:15PM  Biogen Spinoff Bioverativ Squares Off With Roche After $400 Million Buy Investor's Business Daily
03:02PM  Roche investigating case of patient illness after taking MS drug Reuters
07:00AM  What do expensive drugs have in common? A new study breaks it down. American City Business Journals
01:30AM  Biogens FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS Business Wire
May-22-17 08:20AM  Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment TheStreet.com
May-21-17 09:03AM  Why Long-Term Investors Should Prefer Celgene Over Biogen Motley Fool
May-19-17 04:30PM  Amgen, Gilead, Biogen Won't Lead The Biotech Boom So Who Will? Investor's Business Daily
01:09PM  5 Reasons Big Biotech Could Gain 25%-30% Barrons.com
12:02PM  Why Stay Bullish On Gilead Barrons.com
May-18-17 09:28AM  Biogen has acquired Remedy Pharma's stroke medication for $120 mln MarketWatch
09:00AM  Biogen Acquires Remedy Pharmaceuticals Late-Stage Drug CIRARA Business Wire
May-17-17 04:01PM  Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference Business Wire
07:53AM  Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal Zacks
May-16-17 04:51PM  This Funds Picks Gained 200% In A Year And Why No One Knows About It Insider Monkey
03:24PM  Biogen (BIIB) Buys Stroke Candidate Cirara for $120M Zacks
09:20AM  Biogen wins dismissal of investor suit over Tecfidera patient death American City Business Journals
09:17AM  Biogen nabs stroke treatment for $120M, eyeing late-stage trial American City Business Journals
May-15-17 05:59PM  John Paulson Takes A Shine To Telecom The Wall Street Journal
07:30AM  Biogen Acquires Remedy Pharmaceuticals CIRARA for Large Hemispheric Stroke Business Wire
May-14-17 06:10PM  Biogen loses chief scientific officer, but agrees to fund his Harvard lab American City Business Journals
May-12-17 06:00AM  10 Growth Stocks at Reasonable Prices Morningstar
May-11-17 03:45PM  Ionis Pharmaceuticals Inc.'s First Royalties Roll In Motley Fool
09:01AM  Edited Transcript of BIIB earnings conference call or presentation 25-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 09:00AM  BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience GlobeNewswire
May-09-17 03:05PM  Richard Pzena Invests in 3 Health Care Companies GuruFocus.com
May-08-17 05:24PM  4 Drug Stocks Poised to Beat this Earnings Season Zacks
04:12PM  ETFs with exposure to Biogen, Inc. : May 8, 2017 Capital Cube
02:57PM  BioMarin: Is Profitability On The Horizon? Barrons.com
May-07-17 11:42AM  Why Biogen Inc. Shareholders Have Something to Worry About Motley Fool
10:15AM  Huge Hedge Fund, Biotech and Technology Trades Highlight Insider Buying: Apollo Global, Biogen, Twitter, DDR and More 24/7 Wall St.
May-05-17 10:49PM  Weekly Top Insider Buys Highlights GuruFocus.com
09:30AM  The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson Zacks
07:40AM  [$$] Big Sales by Biogen CFO Don't Deter Buying Barrons.com
May-04-17 01:00PM  Insiders Are Loading Up on Twitter, Biogen & More TheStreet.com
10:56AM  What's in the Cards for Ionis (IONS) this Earnings Season? Zacks
07:00AM  What's Behind Ionis Pharmaceuticals' 20% Rally In April Motley Fool
May-03-17 04:29PM  Biogen Inc. -- Moody's revised Biogen's outlook to stable; affirms Baa1 Moody's
May-02-17 06:55PM  Neighborhood Health Plan changes course, will cover Biogen drug for all patients American City Business Journals
May-01-17 10:33AM  Neurotrope Alzheimer's drug data fails to impress; shares crater Reuters
09:06AM  Biogen Pursuing Investigational Candidates in Alzheimers Disease Market Realist
07:36AM  Biogens Targeted Marketing Strategy for Spinraza in 1Q17 Market Realist
Apr-28-17 03:45PM  ETFs with exposure to Biogen, Inc. : April 28, 2017 Capital Cube
02:20PM  What's Worrying Me About Biogen Motley Fool
10:36AM  Biogen Has Developed a Robust Access Strategy for Spinraza Market Realist
09:06AM  Biogens Spinraza Witnessed Robust Patient Demand in 1Q17 Market Realist
08:02AM  These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016 Motley Fool
07:37AM  How Biogens Tysabri and Zinbryta Performed in 1Q17 Market Realist
Apr-27-17 05:16PM  Mixed bag for biotech earnings CNBC Videos
11:02AM  Biogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2017 By the Numbers : April 27, 2017 Capital Cube
10:39AM  Biogen Still Dominated the Multiple Sclerosis Market in 1Q17 Market Realist
09:08AM  Analysts Recommendations for Biogen in 1Q17 Market Realist
07:39AM  Biogen Reports Strong Revenue Growth in 1Q17 Market Realist
Apr-26-17 03:55PM  Biogen Inc. Earnings: New Drug Sparks Life Motley Fool
02:55PM  Hyde Park boy with rare disease wins appeal, will receive Biogen drug American City Business Journals
10:26AM  Stock Market News for April 26, 2017 Zacks
08:42AM  Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : April 26, 2017 Capital Cube
08:18AM  Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug Zacks
07:30AM  Today's Research Reports on Stocks to Watch: Lockheed Martin and Biogen Accesswire
07:20AM  Better Buy: Amgen Inc. vs. Biogen Motley Fool
Apr-25-17 05:42PM  Spinraza's Fast Start Puts Ionis on a Path to Profit Motley Fool
04:45PM  Biogen Earnings Top As $125,000 Drug Starts Well Investor's Business Daily
03:01PM  Biogen and Alzheimers: Theres a Fundamental Problem Here Motley Fool
10:46AM  Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong Zacks
10:22AM  Biogen: Stuck in a Rut? Barrons.com
09:59AM  Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers TheStreet.com
09:51AM  Biogen shares jump as launch of new drug beats expectations American City Business Journals
09:50AM  US STOCKS-Nasdaq breaches 6,000 mark for first time ever Reuters
09:34AM  Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch TheStreet.com
08:58AM  Biogen's Excellent Q1 Bodes Well for Biotech Investopedia
08:50AM  Morning Movers: More Stocks Than I Know What To Do With! Barrons.com
08:36AM  Biogen (BIIB) Beats on Q1 Earnings and Revenue Zacks
08:26AM  Earnings Preview: What To Expect From Amgen On Wednesday Forbes
07:15AM  Biogen Surges After Sales of Drug for Deadly Muscle Disease Beat Estimates Bloomberg
07:14AM  Biogen stock rises after first-quarter earnings, profit beat MarketWatch
07:10AM  Drugmaker Biogen's revenue rises 3 percent Reuters
07:08AM  Biogen tops Street 1Q forecasts Associated Press
06:59AM  Biogen Reports First Quarter 2017 Revenues of $2.8 Billion Business Wire
Apr-24-17 04:28PM  Pricey rare disease drugs launch will be likely focus of Biogen earnings MarketWatch
02:49PM  Biotech: 3 Things to Focus on as Biogen and Amgen Report Barrons.com
09:06AM  3 Key Factors to Look Out for in Biogen's Q1 Results Zacks
08:50AM  Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales TheStreet.com
07:30AM  TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment Business Wire
07:30AM  Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy Business Wire
05:52AM  Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS Zacks
Apr-23-17 11:01AM  3 Stocks That Growth Investors Should Love Motley Fool
Apr-21-17 04:13PM  Street Watches To See If $125,000 Drug Boosts Biogen's Results Investor's Business Daily
02:38PM  Biogen Says It's Back and Ready for Highly Active Dealmaking Bloomberg
02:00PM  Biogens SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy Business Wire
Apr-20-17 05:53PM  What to expect from biotech CNBC Videos
10:16AM  What's in Store for Biogen (BIIB) this Earnings Season? Zacks
09:42AM  Innoviva director vote drama hands last-minute loss to Sarissa Reuters
Apr-19-17 10:09PM  Activist Sarissa says Innoviva backed out of proxy settlement deal Reuters
11:42AM  Gilead Sciences: Who's Frustrated Now? Barrons.com
Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company's Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin's lymphoma; and Aducanumab and E2609 for Alzheimer's disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company's Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,73604,663May 04 04:16 PM
Vounatsos MichelChief Executive OfficerMay 01Buy271.351,402380,4332,927May 02 04:18 PM
DENNER ALEXANDER JDirectorApr 27Buy278.5073,85820,569,476383,858May 01 05:47 PM
Clancy Paul JExecutive VP and CFOApr 25Sale290.009,8922,868,68010,813Apr 27 04:23 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratApr 03Sale274.081,981542,9527,060Apr 04 04:18 PM
Clancy Paul JExecutive VP and CFOMar 13Sale291.559,8912,883,72120,705Mar 14 07:32 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.004810718Mar 03 06:07 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratMar 01Sale290.07973282,2389,041Mar 03 06:02 PM
Clancy Paul JExecutive VP and CFOFeb 28Option Exercise0.006,780031,948Mar 02 05:24 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 28Option Exercise0.004,785010,398Mar 02 05:22 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 28Option Exercise0.005,559036,024Mar 02 05:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 28Option Exercise0.0068104,508Mar 02 05:18 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffFeb 28Option Exercise0.002,06409,237Mar 02 05:16 PM
DiPietro KennethEVP Human ResourcesFeb 28Option Exercise0.005,69608,260Mar 02 05:12 PM
Vounatsos MichelChief Executive OfficerFeb 27Buy285.391,333380,4251,434Mar 01 04:18 PM
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM